Sun Pharma Recalls Venlafaxine Hydrochloride Extended-Release Tablets for Dissolution Failures
Sun Pharma Global Inc. is recalling specific batches of Venlafaxine Hydrochloride Extended-Release Tablets because they failed dissolution specifications and a 12-month stability time point.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically involves a situation where use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences. The specific failure of dissolution and stability specifications represents a quality defect that may affect efficacy but is not associated with reported serious injury or death in the source text.
Plain-English summary
Sun Pharma Global Inc. is recalling 68,194 bottles of Venlafaxine Hydrochloride Extended-Release Tablets, 37.5 mg, in 30-count and 90-count sizes. The affected products were manufactured for Sun Pharma Global Inc. in Dubai, United Arab Emirates, by Sun Pharmaceutical Industries Limited in Halol, India. The recall covers batches JKM3855A, JKM3855B, JKM7265A, and JKM7265B, which were distributed nationwide and in Puerto Rico.
The recall was initiated because the affected tablets failed to meet dissolution specifications and a 12-month stability time point. These quality control failures mean the medication may not release the active ingredient as intended or may not remain stable over its shelf life.
Consumers and healthcare providers should stop using the affected products and return them to the pharmacy or point of purchase for a refund or replacement. Patients should consult their healthcare provider for alternative treatment options if necessary.
The recalled product
- Product
- Venlafaxine Hydrochloride Extended-Release Tablets, 37.5 mg, 30-count bottles and 90-count bottles, RX only, Manufactured for Sun Pharma Global Inc. Dubai, United Arab Emirates by Sun Pharmaceutical Industries Limited, Halol, India
- Manufacturer
- Sun Pharma Global Inc.
- Category
- Drug — Antidepressant
- Affected units
- 68,194
Distribution
Related recalls
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paroxetine Hydrochloride Extended-Release Tablets for Dissolution Failure
FDA (Drugs) · 2026-10-07
- ModerateAjanta Pharma Recalls Ranolazine Tablets for Dissolution Failure
FDA (Drugs) · 2026-10-07
- ModerateMylan Recalls Mycophenolate Mofetil Injection Due to Dissolution Failures
FDA (Drugs) · 2026-09-09
- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
Similar recalls
- ModerateCaraco Recalls Venlafaxine Hydrochloride Extended-Release Tablets for Dissolution Failures
FDA (Drugs) · 2014-05-07
- ModerateSun Pharma Recalls Levetiracetam Extended Release Tablets for Dissolution Failure
FDA (Drugs) · 2015-02-18
- ModerateSun Pharmaceutical Recalls BuPROPion Hydrochloride Tablets for Dissolution Failures
FDA (Drugs) · 2017-02-01
- ModerateCaraco Recalls Venlafaxine Hydrochloride Extended-Release Tablets for Dissolution Failure
FDA (Drugs) · 2014-05-07
- ModerateVenlafaxine Extended-Release Capsules Recalled for Failed Dissolution
FDA (Drugs) · 2024-07-10
- LowSun Pharma Recalls Bupropion Hydrochloride Tablets for Dissolution Failure
FDA (Drugs) · 2015-08-26